Actively Recruiting
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Led by Alnylam Pharmaceuticals · Updated on 2026-04-24
10
Participants Needed
7
Research Sites
532 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
CONDITIONS
Official Title
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before last menstrual period or at any point during pregnancy
You will not qualify if you...
- There are no exclusion criteria for participation in this program.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Clinical Trial Site
Iowa City, Iowa, United States, 52242
Actively Recruiting
2
Clinical Trial Site
Nantes, France
Actively Recruiting
3
Clinical Trial Site
Münster, Germany
Actively Recruiting
4
Clinical Trial Site
Pavia, Italy
Actively Recruiting
5
Clinical Trial Site
Groningen, Netherlands
Actively Recruiting
6
Clinical Trial Site
Lisbon, Portugal
Actively Recruiting
7
Clinical Trial Site
Madrid, Spain
Actively Recruiting
Research Team
A
Alnylam Clinical Trial Information Line
CONTACT
A
Alnylam Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here